ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Digoxin

Also written as “digoxin”, “ZT002 injection, rosuvastatin, digoxin” and “Digoxin (0.25mg)”.

Its studies are mostly in Obesity · Neoplasms · Thalassemia · Carcinoma, Non-Small-Cell Lung · Liver Cirrhosis, led by 25 companies.

Drug pageDigoxin: every studyMany companies study it; this page follows only the 43 they lead. All 87 studies, academic ones too, with its approvals and label.
Furthest: phase 2, since Jun 1, 201043 company-led studies, 1 open or runningNext primary completion: Dec 5, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim90 open or runningphase 1since Jun 1, 2010Jun 1, 2010none ahead
AstraZenecaits history only30 open or runningphase 1since Jul 8, 2008Jul 8, 2008none ahead
Bristol-Myers Squibbits history only30 open or runningphase 1since Oct 9, 2014Oct 9, 2014none ahead
Astellas Pharmaits history only20 open or runningphase 1since Apr 29, 2014Apr 29, 2014none ahead
GlaxoSmithKlineits history only20 open or runningphase 1since Mar 28, 2008Mar 28, 2008none ahead
Hoffmann-La Rocheits history only20 open or runningphase 1since Jan 9, 2013Jan 9, 2013none ahead
Johnson & Johnsonits history only20 open or runningphase 1since Jan 20, 2011Jan 20, 2011none ahead
Merckits history only20 open or runningphase 1since Aug 26, 2024Aug 26, 2024none ahead
Sanofiits history only20 open or runningphase 1since May 19, 2011May 19, 2011none ahead
AbbVieits history only10 open or runningphase 1since Feb 3, 2016Feb 3, 2016none ahead

Also a collaborator on its studies: Parexel, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene and Medpace.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boehringer Ingelheim only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 1, 2010First study: phase 1 study in HealthyFirst studyNCT01134965 · 24 enrolled · Germany
  2. Feb 28, 2011Phase 1 study in HealthyNCT01306175 · 20 enrolled · Germany
  3. Jun 20, 2014Phase 1 study in HealthyNCT02171052 · 24 enrolled
  4. Sep 3, 2014Phase 1 study in HealthyNCT02231931 · 24 enrolled · Germany
  5. Jan 20, 2015Phase 1 study in HealthyNCT02345304 · Germany
  6. Aug 1, 2016Phase 1 study in HealthyNCT02854527 · 30 enrolled · Germany
  7. Oct 6, 2017Phase 1 study in HealthyNCT03307252 · 45 enrolled · Germany
  8. Oct 15, 2020Phase 1 study in HealthyNCT04590937 · 15 enrolled · Germany
  9. Feb 14, 2023No phase study in Liver CirrhosisNCT05741372 · 28 enrolled · Germany

TargetBeta

“Sodium/potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same 8 targets

ProgramCompanyFurthest phaseStudies
Istaroximerulewindtree-therapeuticsphase 38

Studies

All 9 Boehringer Ingelheim leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05741372Liver Cirrhosis · Germany–CompletedDec 18, 202428
NCT04590937Healthy · Germany1CompletedJan 11, 202115
NCT03307252Healthy · Germany1CompletedMay 2, 201845
NCT02854527Healthy · Germany1CompletedNov 11, 201630
NCT02345304Healthy · Germany1WithdrawnApr 20150
NCT02231931Healthy · Germany1CompletedJan 1, 201524
NCT02171052Healthy1CompletedAug 200624
NCT01306175Healthy · Germany1CompletedApr 201120
NCT01134965Healthy · Germany1CompletedJul 201024

How it is read

Names in the registry

  • “Digoxin”, 33 entries
  • “digoxin”, 6 entries
  • “ZT002 injection, rosuvastatin, digoxin”, 1 entry
  • “Digoxin (0.25mg)”, 1 entry
  • “Lenoxin®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.